Sanofi’s Tzield Approved In US For Recently Diagnosed Stage 3 Type 1 Diabetes In Children

Sanofi’s Tzield Approved For Stage 3 Type 1 Diabetes

Sanofi has announced that the US Food and Drug Administration has granted accelerated approval for Tzield, also known as teplizumab-mzwv, for certain children recently diagnosed with stage 3 type 1 diabetes. The approval applies to children aged 8 to 17 years who have recently been diagnosed with stage 3 type 1 diabetes. Tzield is intended … Read more